We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clear cell renal carcinoma - evolution of metastatic disease and overall survival after four lines of targeted therapy. Case report.
- Authors
Lăzescu, Andreea; Ciurea, Laura; Burlănescu, Ioan; Mitulescu, Dragoş; Grigorescu, Alexandru
- Abstract
In this presentation we will bring to your attention the case of a patient with clear cell renal carcinoma and the disease extended by multiple pulmonary, lymphatic, bone and liver metastases, classified according to the prognostic criteria in the intermediate risk group. The patient benefited from right nephrectomy with right partial adrenalectomy followed by four consecutive targeted therapies for metastatic disease: two lines of tyrosine kinase inhibitors (sunitinib in the first line and sorafenib in the second line), followed by two lines of mTOR inhibitors (temsirolimus and everolimus). The monitoring of disease progression was performed periodically through clinical and paraclinical examinations, computed tomography, bone scan and MRI examinations. The therapeutic line was changed every time the disease progressed. We experienced a spectacular patient survival under four treatment lines of 45 months in metastatic disease, compared to a statistically estimated median survival period of 22.5 months for patients with metastatic renal cancer in the intermediate risk group. We basically observed that for this patient the survival was double.
- Subjects
RENAL cancer patients; COMPUTED tomography
- Publication
Oncolog-Hematolog, 2017, Issue 41, p32
- ISSN
2066-8716
- Publication type
Article
- DOI
10.26416/onhe.41.4.2017.1349